Overview of Dr. Sarva
Dr. Harini Sarva is a neurologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and New York-Presbyterian Hospital. She received her medical degree from State University of New York Downstate Medical Center College of Medicine and has been in practice 13 years. She is one of 484 doctors at New York-Presbyterian Hospital and one of 484 doctors at New York-Presbyterian Hospital who specialize in Neurology. She has more than 60 publications and over 500 citings.
Office
428 E 72nd St
Ofc 400
New York, NY 10021Fax+1 212-746-8296
Education & Training
- SUNY Downstate Health Sciences UniversityResidency, Neurology, 2008 - 2012
- State University of New York Downstate Medical Center College of MedicineClass of 2004
Certifications & Licensure
- NY State Medical License 2011 - 2026
- NJ State Medical License 2020 - 2023
- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants Start of enrollment: 2022 Oct 05
Roles: Principal Investigator
Publications & Presentations
PubMed
- 11 citationsA prospective crossover trial of botulinum toxin chemodenervation versus injection augmentation for essential voice tremor.Christine Estes, Babak Sadoughi, Rachel Coleman, Harini Sarva, Elizabeth Mauer
The Laryngoscope. 2018-02-01 - 20 citationsPrimary familial brain calcification.Melvin Parasram, J. Levi Chazen, Harini Sarva
The Journal of the American Osteopathic Association. 2020-11-01 - 10 citationsSecondary orthostatic tremor in the setting of cerebellar degeneration.Harini Sarva, William Severt, Nuri Jacoby, Seth L. Pullman, Rachel Saunders-Pullman
Journal of Clinical Neuroscience. 2016-05-01
Press Mentions
- BlueRock Therapeutics to Incorporate Wearable and Invisible Contactless Digital Health Technologies from Rune Labs and Emerald Innovations in Parkinson’s Disease Clinical TrialMarch 14th, 2023
- BlueRock Therapeutics Announces Completion of Enrollment of Phase 1 Trial in Patients with Parkinson's DiseaseMay 31st, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: